Introduction
============

Hemodialysis (HD) in end-stage renal disease (ESRD) patients is associated with the development of oxidative stress, caused by the impairment of antioxidant defences and the bioincompatibility of the dialysis technique contributing to cardiotoxic effects ([@b5-bmi-03-419]).

Reactive oxygen species (ROS) are known to play a role in the pathogenesis and progression of chronic renal failure (CRF). Apart from the kidney disease itself and the uremia, numerous other factors appear to contribute to oxidative stress ([@b58-bmi-03-419]), including HD via contact activation of neutrophils by the artificial surfaces of the dialysis membrane and the tubing system ([@b64-bmi-03-419]).

Increased levels of oxidants (e.g. malonic dialdehyde) and lower levels of antioxidants (glutathione, α-tocopherol) in CRF patients play an important role in the development of endothelial dysfunction, atherogenesis and cardiovascular disease ([@b26-bmi-03-419]; [@b10-bmi-03-419]; [@b7-bmi-03-419]; [@b6-bmi-03-419]; [@b35-bmi-03-419]; [@b53-bmi-03-419]; [@b27-bmi-03-419]; [@b44-bmi-03-419]; [@b45-bmi-03-419]). A more specific biomarker of oxidative stress represents HNE, one of the major end products of lipid peroxidation generated mainly from arachidonic acid. HNE has cytotoxic and mutagenic properties, induces apoptosis, NF-κB activation and inhibition of enzyme activities ([@b13-bmi-03-419]; [@b52-bmi-03-419]; [@b20-bmi-03-419]; [@b43-bmi-03-419]; [@b53-bmi-03-419]; [@b60-bmi-03-419]; [@b37-bmi-03-419]).

Previously, first reports on F~2~-isoprostanes as indicators of lipid peroxidation in renal diseases were published ([@b54-bmi-03-419]; [@b21-bmi-03-419]; [@b22-bmi-03-419]; [@b25-bmi-03-419]; [@b9-bmi-03-419]; [@b14-bmi-03-419]; [@b24-bmi-03-419]; [@b66-bmi-03-419]). F~2~-Isoprostanes have been established as chemically stable, highly specific and reliable biomarkers of *in vivo* oxidative stress, which can be very sensitively measured by gas chromatography/mass spectrometry ([@b31-bmi-03-419]). Measurements in dialysis patients before dialysis showed higher plasma levels of F~2~-isoprostanes than in control subjects ([@b54-bmi-03-419]; [@b21-bmi-03-419]). But the data are not unique: in contrast to the data of [@b54-bmi-03-419] and of [@b21-bmi-03-419], [@b11-bmi-03-419] did not find an increase in plasma and urinary F~2~-isoprostanes in patients with nephrotic syndrome.

Both arachidonic acid oxidation products, F~2~-isoprostanes and HNE, are known to be involved in atherogenesis and myocardial injury ([@b4-bmi-03-419]; [@b37-bmi-03-419]; [@b31-bmi-03-419]), which is the most critical point of life quality and mortality in CRF ([@b15-bmi-03-419]; [@b48-bmi-03-419]). There are also strong interactions between both types of cardiovascular risk factors, e.g. HNE induces the formation of 8-iso-PGF~2α~ in vascular smooth muscle cells ([@b37-bmi-03-419]).

HD patients are not only exposed to enhanced oxidative stress, but also to inflammation ([@b54-bmi-03-419]). Cardiovascular mortality remains high in ESRD patients, particularly in the group with evidence for inflammation ([@b68-bmi-03-419]). Inflammation may enhance oxidative stress through increased free radical generation via activation of NADPH oxidase and may directly modify proatherogenic factors.

The aim of this paper is 1. to determine F~2~-isoprostanes and HNE in the serum of ESRD patients before and following HD and for comparison in healthy control persons and 2. to examine if the markers of oxidative stress are correlated to the degree of inflammation and/or to the degree of renal anemia.

Patients and Methods
====================

Patients
--------

Patients and probands were required to provide written informed consent before the start of the evaluation. The place of dialysis was at the dialysis centre of Scorrano, Italy. Inclusion criteria of patients were as follows: presence of renal anemia (hemoglobin concentration\<11 g/dl, time on dialysis \>6 months, treatment in the center \>3 months, normal values of GOT, GPT, LDH and γ-GT. Among the egligible patients the anamnesis about their life style required to exclude 12 persons because of smoking. Further criteria of exclusion were: patients taking antioxidants, patients with acute infection, with considerable iron overload, with an acute phase of rheumatological disorders and with neoplasiae. Furthermore, HD patients without well-functioning vascular excess and patients treated by vitamin E-bounded membranes were excluded. Only one patient was excluded at the end of the dialysis study because of wrong sampling. 14 patients came with hypertension. We aimed a strict control of hypertension with a target blood pressure ≤130/80 mm Hg (β-receptor blocker, ACE-I inhibitors, angiotensin II receptor blocker). For the investigated patients the "dry" weight was defined by impedenziometry and the "dry" weight was reached at the end of the HD session. 12 patients had intima media thickness and five of them had also documented one or more carotid plaques measured by B-mode ultrasonography. For 11 patients a left ventricular hypertrophy was documented, 16 patients were treated with erythropoietin. All patients were treated three times/week. High flux dialysis filters consisting of polysulphone/polyacrylonitrile were used. The evaluation was done at the midweek dialysis session. The participants of the control group were healthy persons from the dialysis centers in Scorrano and Berlin (nurses, doctors, technicians etc.). F~2~-isoprostane concentrations (8-iso-PGF~2α~ and 9α,11α-PGF~2α~) and HNE in correlation to CRP and hemoglobin content were analysed in 14 non-diabetic HD patients with chronic renal failure (6 male, 8 female, middle age 59 ± 14 years). F~2~-isoprostanes before and following hemodialysis were compared in 19 non-diabetic ESRD patients (5 additional patients: 2 male, 3 female, from the same age group). There were also control groups for analysis of F~2~-isoprostanes with 65 (30 male, 35 female, middle age 55 ± 15 years) and for analysis of HNE with 131 healthy probands (77 male and 54 female, middle age 60 ± 10 years).

Sample extraction, hydrolysis and purification of F**2**-isoprostanes
---------------------------------------------------------------------

The determination of the concentrations of F~2~-isoprostanes (sum of esterified and non-esterified isomers) was carried out as described previously ([@b65-bmi-03-419]) with some modifications. To hydrolyze esterified lipids, the serum samples (1.0 mL) were treated with 320 μL of KOH (1 mol/L) at 40 °C for 30 min. Thereafter, the samples were neutralized by addition of 3 mL HCl (0.1 mol/L), and the pH was adjusted to 2 with HCl (1 mol/L). 9α,11α-PGF~2α~-d~4~ (1 ng in 20 μL ethanol) was added as internal standard. The samples were centrifuged at 5,000 × *g* for 15 min, and the supernatant was applied onto a C18-cartridge, pre-washed with 5 mL of methanol and 5 mL of water. The cartridge was then washed with 10 mL HCl (0.1 mol/L) and 10 mL of acetonitrile/water (15/85, v/v). Isoprostanes were eluted from the column with 5 mL of n-hexane/ethyl acetate/2-propanol (30/65/5, v/v/v). The prostanoid extract was applied then onto a NH~2~-cartridge, pre-washed with n-hexane (10 mL). The column was successively washed with 10 mL of n-hexane/ethyl acetate (30/70, v/v), acetonitrile/water (90/10, v/v) and acetonitrile. Finally, F~2~-isoprostanes were eluted with 5 mL of ethyl acetate/methanol/acetic acid (10/85/5, v/v/v).

Derivatization and GC-MS/negative ion chemical ionization analysis
------------------------------------------------------------------

The extracts from the NH~2~-chromatography step were evaporated to dryness under a stream of argon at 45 °C. The residues were reconstituted with 40 μL of pentafluorobenzyl-bromide (10% in acetonitrile) and 20 μL of *N,N*-diisopropylethylamine (10% in acetonitrile) and incubated at 45 °C for 30 min. Thereafter, 50 μL of *bis*-(trimethylsilyl) trifluoroacetamide (BSTFA) and 5 μL of N,N-diisopropylethylamine were added to the dried sample. The samples were kept at 45 °C for 45 min, the solvents were removed, and the samples were reconstituted in 40 μL isooctane containing 0.1% BSTFA. F~2~-isoprostanes were separated by GC/MS using the following temperature program: initial temperature of 175 °C for 2 min; with a rate of 30 °C/min to a final temperature of 270 °C maintained for 20 min; total run time: 25.2 min. Quantitative analysis was performed with ammonia as reagent gas using selected ion monitoring (SIM) of the carboxylate anion \[M-181\]^−^ at *m/z* 569 and 573 for F~2~-isoprostanes and 9α,11α-PGF~2α~-d~4~, respectively. The *m/z* 569 ion current chromatogram showed the occurrence of two major peaks in serum samples, peak I co-eluting with authentic 8-iso-PGF~2α~ and peak II co-eluting with authentic 9α,11α-PGF~2α~. Peak I is expected to contain exclusively F~2~-isoprostanes, whereas peak II may contain both, mainly F~2~-isoprostanes, but additionally cyclooxygenase-derived PGF~2α~ ([@b65-bmi-03-419]).

The response factors for the isoprostane isomers were 1.00 and 0.55 for 9α,11α- and 8-iso-PGF~2α~, respectively (means of three separate determinations).

F~2~-isoprostane analyses were performed in triplicate throughout for each plasma sample.

Determination of CRP and hemoglobin
-----------------------------------

CRP was measured by immunoturbidimetry ([@b19-bmi-03-419]), and hemoglobin with spectrophotometric methods within the clinical laboratory routine parameters. CRP and hemoglobin concentrations were 16.6 ± 3.8 mg/L serum resp. 9.75 ± 0.64 g/dl (mean ± SEM n = 14) for HD patients and 3.3 ± 0.1 resp. 15.1 ± 0.4 (mean ± SEM, n = 131; p \< 0.05 resp. p \< 0.01; patients versus controls) for healthy control persons.

4-Hydroxynonenal (HNE) analysis
-------------------------------

The measurement of HNE includes the modification of this aldehyde with dinitrophenylhydrazine, the thin layer chromatographic analysis of the dinitrophenylhydrazones in three groups, and finally the isocratic analysis of the dinitrophenylhydrazine derivatives of the 4-hydroxyalkenales ([@b12-bmi-03-419]; [@b20-bmi-03-419]; [@b52-bmi-03-419]). During the HPLC-analysis a mixture of methanol and water (4:1, v:v) was used as an eluent. The detection-wavelength was set to 378 nm. The HNE-standard was produced from the diacetale which was stored in a chloroform solution at −20 °C.

Statistical analyses
--------------------

All data are presented as mean ± SEM. Comparisons between independent groups (patients versus controls) have been performed with the two-sample t test, comparisons between dependent groups (before and after dialysis) with the t test for paired data. Correlations between variables have been investigated with linear regression and Pearson's correlation coefficient. All tests have been carried out two-sided and P values below 0.05 were considered to be significant.

Results
=======

Data concerning serum concentrations of F~2~-isoprostanes as biomarkers of the oxidative status of HD patients and normal control persons are shown in [Figure 1](#f1-bmi-03-419){ref-type="fig"}. It can be seen that HD patients (4.69 ± 0.81 and 3.56 ± 0.42 pmol/mL) exhibited 4.2-fold (8-iso-PGF~2α~) and 2.8-fold (9α,11α-PGF~2α~) higher F~2~-isoprostane serum levels than healthy controls (1.12 ± 0.05 and 1.28 ± 0.11 pmol/mL). Furthermore, F~2~-isoprostane concentrations did not significantly change in patients before and following hemodialysis, as was shown in [Figure 2a and 2b](#f2-bmi-03-419){ref-type="fig"}.

For 8-iso-PGF~2α~ and 9α,11α-PGF~2α~, correlations with a representative parameter of inflammation (CRP) and with a representative parameter of the degree of renal anemia (hemoglobin concentration) were examined. [Figure 3](#f3-bmi-03-419){ref-type="fig"} shows the correlations of F~2~-isoprostane concentrations \[9α,11α-PGF~2α~ ([Fig. 3a](#f3-bmi-03-419){ref-type="fig"}) and 8-iso-PGF~2α~ ([Fig. 3b](#f3-bmi-03-419){ref-type="fig"})\] and CRP as parameter for inflammatory processes in the patients. We demonstrated a positive correlation of total (esterified plus free) F~2~-isoprostane isomers with the degree of inflammation, whereas no correlation between F~2~-isoprostanes and the degree of renal anemia (hemoglobin content) was found (not documented here).

In contrast, HNE, formed as one of the main degradation products of arachidonic acid, which is significantly increased in serum samples of ESRD patients ([Fig. 4a](#f4a-bmi-03-419){ref-type="fig"}), changed in dependence on hemoglobin concentrations, i.e. the HNE levels were higher with decreasing hemoglobin. It showed, therefore, an inverse relationship (significant negative correlation) with the degree of renal anemia ([Fig. 4b](#f4b-bmi-03-419){ref-type="fig"}). However, no significant correlation between the levels of HNE and the C-reactive protein (degree of inflammation) was observed (not shown).

Discussion
==========

Chronic inflammation in HD patients
-----------------------------------

Many of ESRD and HD patients are in the state of chronic inflammation. The reason why renal failure is a source of inflammation has not been fully elucidated. A multifactorial origin of inflammation may be taken in consideration ([@b55-bmi-03-419]). These include renal insufficiency (leading in the end stage to uremia) and its complications; as already established atherosclerosis, diabetes, hypertension; consequences of renal replacement treatment; back-leakage of endotoxins from contaminated dialysate and frequent infections ([@b59-bmi-03-419]). Less biocompatible HD methods may contribute to the enhanced stimulation of neutrophiles and monocytes (through dialysis membrane interaction), the induction of cytokines, as IL-1, IL-6, TNFα and the increase of CRP ([@b30-bmi-03-419]). Even at initial stages of chronic renal failure, the CRP level is elevated ([@b59-bmi-03-419]). CRP could be a sensitive risk index of the overall morbidity and mortality in CRF patients. As an acute phase protein with high sensitivity and low specificity, CRP is mainly synthesized in the liver and may be regulated largely by circulating levels of IL-6 ([@b57-bmi-03-419]; [@b61-bmi-03-419]).

CRP has many features that may contribute to an inflammatory process: it binds to damaged cells and activates the complement system. It binds to atherogenic lipoproteins and induces aggregation of LDL and VLDL *in vitro*; and stimulates thrombus formation ([@b18-bmi-03-419]). [@b3-bmi-03-419] and [@b18-bmi-03-419] reported that CRP is 5--10-fold higher in HD patients than in healthy controls (16.3 vs. 1.8 mg/L), which is associated with an increased cardiovascular risk. In the group of patients which we investigated the values were 16.6 vs. 3.3 mg/L, i.e. quite similar.

Inflammation may be mainly responsible for oxidative stress
-----------------------------------------------------------

Inflammation is discussed as a well-documented factor influencing the development of oxidative stress in dialysis patients ([@b67-bmi-03-419]). The way by which inflammation can contribute to oxidative stress in chronic renal failure is via activation of NADPH oxidase by interleukins and anaphylatoxins produced during HD sessions and/or myeoloperoxidase ([@b30-bmi-03-419]). Further sources of ROS are the mitochondrial respiratory chain, lipoxygenases, cyclooxygenases, xanthin oxidase, and NO synthase.

Both ROS and their secondary products are involved in the pathophysiological processes in ESRD. Oxidative stress, resulting from imbalance between oxidant production and antioxidative defence mechanisms, has been documented in ESRD patients using lipid, protein, nucleic acid and carbohydrate oxidative markers (Paleschi et al. 2007; [@b38-bmi-03-419]; [@b8-bmi-03-419]; [@b36-bmi-03-419]; [@b32-bmi-03-419]).

A highly significant positive correlation was observed between logCRP and reactive oxygen metabolites in HD patients by Samouilidou et al. 2007. F~2~-isoprostanes, associated with the inflammation process in patients on HD, positively correlated with CRP ([@b21-bmi-03-419]; [@b22-bmi-03-419]) as also described in this paper. HNE, however, as readily diffusible molecule upon dialysis doesn't follow the increase of CRP in chronic renal failure ([@b45-bmi-03-419] and this study). Interestingly, an inverse correlation between HNE and hemoglobin serum concentrations could be demonstrated and therefore a role of HNE as predictor of hemolytic anemia was suggested.

Esterified F**2**-isoprostanes may be not only reliable biomarkers of oxidative stress, but also mediators of inflammation
--------------------------------------------------------------------------------------------------------------------------

Measurement of F~2~-isoprostanes has advantages over other quantitative markers of oxidative stress: they are chemically stable, specific products of lipid peroxidation, they are formed *in vivo* and are present in all normal tissues and biological fluids ([@b29-bmi-03-419]). GC-MS is the reference analytical method for isoprostane measurement in biological fluids and tissues. F~2~-isoprostanes are widely accepted to correlate with the cardiovascular risk in human beings ([@b22-bmi-03-419]). This is an additional argument for the use of F~2~-isoprostanes in ESRD, which is closely connected with cardiac insufficiency.

F~2~-isoprostanes have been found to exert potent biological actions and therefore may participate as pathophysiological mediators of disease ([@b29-bmi-03-419]). In patients with lung diseases, 8-iso-PGF~2α~ concentrations in exhaled breath condensate reflect the degree of airway inflammation ([@b28-bmi-03-419]) with high levels reported in patients with chronic obstructive pulmonary disease and in smokers. 8-iso-PGF~2α~ is not only known as a pulmonary, but also as a potent renal vasoconstrictor. In the rat, F~2~-isoprostanes reduce glomerular filtration rate and renal blood flow by 40%--45% in the low nanomolar range ([@b56-bmi-03-419]). F~2~-isoprostanes have important *in vitro* activities that could be relevant to the pathophysiology of atherosclerosis. They promote platelet activation ([@b34-bmi-03-419]) and induce mitogenesis in vascular smooth muscle cells ([@b17-bmi-03-419]). Moreover, F~2~-isoprostane formation is increased during LDL oxidation *in vitro* and F~2~-isoprostanes are major contributors to the proadhesive effect induced by minimally oxidatively modified LDL on neutrophils ([@b16-bmi-03-419]). F~2~-isoprostanes exert their biological effects by receptor-mediated interactions (acting as full or partial agonists at thromboxane receptors) and also by receptor-independent mechanisms ([@b29-bmi-03-419]).

F~2~-isoprostane serum levels of HD patients in this study were significantly increased versus healthy control persons. This is in agreement with other reports ([@b62-bmi-03-419]; [@b21-bmi-03-419]; [@b25-bmi-03-419]). But, there were no significant differences of F~2~-isoprostane levels before and after HD, as was also found by [@b21-bmi-03-419], and in contrast to [@b24-bmi-03-419], who observed 4-fold higher levels post hemodialysis.

Both human and experimental studies have indicated associations of F~2~-isoprostanes and severe inflammatory conditions, diabetes and atherosclerosis. Recently it was shown that intravenous administration of 8-iso-PGF~2α~ induced cyclooxygenase-mediated prostaglandin (PGF~2α~) formation and activation of inflammatory responses ([@b1-bmi-03-419]). In another recent study, 8-iso-PGF~2α~ induced IL-8 expression in human macrophages, a chemokine involved in inflammation and atherogenesis through mitogen-activated protein kinases ([@b42-bmi-03-419]). These studies emphasize that F~2~-isoprostranes might be mediators of inflammation involving cyclooxygenases and/or cytokines and promote a possible link between oxidative stress and inflammation.

Increased concentrations of F~2~-isoprostanes are related with high concentrations of CRP. As in our measurements also in those of [@b54-bmi-03-419] and [@b21-bmi-03-419] was found that F~2~-isoprostanes correlate to the concentration of C-reactive protein as one of the most important factors in predicting cardiovascular mortality, which is by far the main cause of mortality in ESRD patients with cardio-renal anemia syndrome ([@b49-bmi-03-419]; [@b50-bmi-03-419], [@b51-bmi-03-419]).

Conclusions and outlook
-----------------------

In this study it was shown that ESRD patients undergoing hemodialysis are exposed to enhanced oxidative stress and to inflammation. The main limitations of this study were the relatively small number of patients and the obviously incomplete consideration of all parameters influencing inflammation and/or oxidative stress (e.g. lipid metabolism, blood pressure, cardiovascular disorders).

Biomarkers of oxidative stress, F~2~-isoprostanes and HNE, are significantly increased in the serum of patients and are highly correlated either to the degree of inflammation or renal anemia as well. Inflammation and oxidative stress may act synergistically to increase cardiovascular morbidity and mortality risk in the patients. The correction of anemia (e.g. by erythropoietin) reduces the oxidative stress to some extent, and also the cardiovascular risk. The prevention of oxidative stress in HD might, however, also focus on improving the hemocompatibility of the dialysis system, the supplementation of antioxidants and the modulation of NADPH oxidase by pharmacological approaches. In order to prove the effectiveness of therapeutic interventions, further efforts are obligatory. These include the enlargement and proper selection of suitable biomarkers that can be related to the pathogenesis and the development of the disease. Concerning F~2~-isoprostanes and partially HNE, most of the strict criteria for validation of the use of a biomarker *in vivo* ([@b69-bmi-03-419]) are appropriate, but they only do reflect the ROS-mediated oxidation of arachidonic acid. Further limitations are 1. that the analysis of the used biomarkers (in particular F~2~-isoprostanes) is labor-intensive and requires expensive equipment and 2. an increase in F~2~-isoprostanes locally in tissues is not detected by measuring systemic oxidant stress. For HD patients it should be taken into account that small molecules, as HNE and possibly free F~2~-isoprostanes (but not esterified) are washed out during dialysis. It would be necessary, therefore, to follow up the serum or plasma concentrations of esterified F~2~-isoprostanes and those of other biomarkers, which have to be defined, very thoroughly in longitudinal studies.
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